About this episode

This episode features an interview discussing marstacimab therapy for hemophilia and new biomarkers for HLH.

In this week's episode, Blood editor Dr. James Griffin interviews Drs. Johnny Mahlangu and Joseph Rocco on their articles published in volume 147 issue 9 of Blood . Dr. Mahlangu discusses study details and next steps from " Efficacy and safety of marstacimab prophylaxis in hemophilia A/B with inhibitors: results from the phase 3 BASIS trial " which shows that bleeding was reduced by 93% with subcutaneous marstacimab. Dr. Rocco shares the development behind " CXCL9 as a novel prognostic marker to identify high-risk adults with hemophagocytic lymphohistiocytosis ", and the insights gained from measuring a new surrogate marker of IFN-γ activity predicting severity and mortality.

People in this episode

Host: Dr. James Griffin

Guests: Dr. Johnny Mahlangu, Dr. Joseph Rocco

Mentioned in this episode

Organizations: Blood

Books & works: Efficacy and safety of marstacimab prophylaxis in hemophilia A/B with inhibitors: results from the phase 3 BASIS trial, CXCL9 as a novel prognostic marker to identify high-risk adults with hemophagocytic lymphohistiocytosis

More episodes of Blood Podcast

• Review Series on Clonal Tracking in Hematopoiesis · June 4, 2026 · 30 min
• Review Series on Hemophagocytic Lymphohistiocytosis (HLH) · May 21, 2026 · 16 min
• IBD augmentation of CHIP and Platelet mTOR's impact on Cerebral Malaria · May 14, 2026 · 21 min

Explore listener stats, chart rankings, contacts and more on the Blood Podcast podcast page.